Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Abstract Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study aimed to explore the efficacy and safety of dacomitinib, a second-generation EGFR tyrosine kinase inhibitor (EGFR-TKIs),...

Descripción completa

Detalles Bibliográficos

Autores principales:	Xingxiang Pu, Yu Zhou, Yi Kong, Bolin Chen, Aifang Yang, Jia Li, Kang Li, Yan Xu, Lin Wu
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMC 2023-10-01
Colección:	BMC Cancer
Materias:	Uncommon EGFR mutation Non-small cell lung cancer Dacomitinib Efficacy Safety
Acceso en línea:	https://doi.org/10.1186/s12885-023-11465-2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!